Stock Analiz

Gyre Therapeutics, Inc. GYRE

Biotechnology: Pharmaceutical Preparations · IPO 2006 · data as of November 13, 2026

$4.31Market cap $497M
Open the interactive analysis →

Gyre Therapeutics, Inc. (GYRE) is a healthcare company listed in the US with a market value of about $497M. In the twelve months to September 30, 2026 it had revenue of $110M and net income of -$25M, a net margin of -22.7%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 41% a year, a 5-year average ROIC of -29%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.

About Gyre Therapeutics

Gyre Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2006. Revenue went from $275000 in 2014 to $117M in 2025, growth of about 73.3% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 36% over three years (dilution for shareholders). It spends 12% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.5
P/B4.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1.6%
Shareholder yield0.0%
Intrinsic value vs. price−89%

Growth and quality

Revenue growth (1 yr)10.2%
Revenue growth (5 yrs, per year)41.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-248.8%
ROIC (5-yr avg.)-29.0%
Profitable years (of last 10)3
Years paying a dividend1

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$110M$117M$106M$113M$102M$7M$21M—$6000$1M—
Net income-$25M$10M$18M-$85M$4M-$88M-$56M-$55M-$30M-$22M-$17M
Free cash flow-$8M-$180000-$6M$17M$6M-$85M—-$44M-$29M-$20M-$19M
EPS (diluted)$-0.23$0.02$0.05$-1.41$0.03$-2.87$-2.93$-4.60$-2.68$-7.45$-21.75
Net margin-22.7%8.5%16.9%-75.3%4.2%-1198.3%-268.5%—-500900.0%-2118.0%—
ROIC—7.3%19.2%—17.1%-159.7%-58.3%-64.5%-22.3%-48.1%-45.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $18.67, 333% above the current price; targets range from $18.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-0.28 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Gyre Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Gyre Therapeutics pay a dividend?

Not currently.

Is Gyre Therapeutics a good stock to buy?

We do not give buy or sell advice. Gyre Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.